O Piniazhko

Biographic Data

ID10242907
NAMEO Piniazhko
FAMILY NAMEO Piniazhko
SIGNATUREPINIAZHKO O
AFFILIATIONSMinistry of Health
ORCID0000-0003-1131-733X
VERIFIEDYes
TOTAL WORKS4
TOTAL CITATIONS0
WORKS AS AUTHOR4
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2020
LATEST PUBLICATION YEAR2023
H-INDEX0

  • Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment

    Open AccessAntal Zemplényi, Konstantin Tachkov et al.ARTICLEFrontiers in Public Health2023

    Background: Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) …

  • Recommendations for patient involvement in health technology assessment in Central and Eastern European countries

    Open AccessIvett Jakab, Maria Dimitrova et al.ARTICLEFrontiers in Public Health2023

    Introduction: Meaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the …

  • Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges

    Open AccessRita Daubner-Bendes, Rita Daubner‐Bendes et al.ARTICLEFrontiers in Public Health2021

    Objectives: Methodological challenges in the evaluation of medical devices (MDs) may be different for early and late technology adopter countries, as well as the potential health technology assessment (HTA) solutions to tackle them. This study aims to provide guidance to Central and Eastern European (CEE) countries on how to address key challenges of HTA for MDs with special focus on the transferability of scientific evidence. Methods: As part of…

  • A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries

    Open AccessMarcin Czech, Aleksandra Baran-Kooiker et al.ARTICLEFrontiers in Public Health2020

    Background: Despite international initiatives on collaboration within the field of rare diseases, patient access to orphan medicinal products (OMPs) and healthcare services differ greatly between countries. This study aimed to create a comprehensive and in-depth overview of rare diseases policies and reimbursement of OMPs in a selection of 12 countries in the Western Eurasian region: Armenia, France, Germany, Kazakhstan, Latvia, The Netherlands, …